摘要
目的:验证合并使用小剂量阿立哌唑治疗抗精神病药(APS)所致高催乳素(PRL)血症的长期疗效及安全性。方法:对APS所致高PRL患者随机分为2组,一组继续使用APS治疗,一组在APS基础上合并使用5 mg·d-1阿立哌唑治疗。观察时间至少为26周。在基线及第4,8,12,26周末进行临床总体印象量表——严重程度(CGI-S)、锥体外系症状评定量表(ESRS)、血清PRL水平测定,记录停药率及停药前服药时间(TTD)。结果:阿立哌唑组PRL在第4周末即明显下降,到第8周末达到稳定水平;对照组患者PRL水平无变化。阿立哌唑组在26周时的停药率为11.1%,对照组26周时停药率为31.1%;阿立哌唑组在第52周时停药率为57.8%,对照组为76.7%;阿立哌唑组与对照组患者停药前的服药时间有显著差异[(297.3±92.6)d vs(193.5±103.1)d,t=6.86,P=0.001]。结论:合并小剂量阿立哌唑治疗抗精神病药所致高催乳素血症的长期效应好,安全性高。
OBJECFIVE To explore the effectiveness and safety of aripiprazole in long term treatment for schizophrenia patients with antipsychotics-induced hyperprolactinemia. METHODS 180 schizophrenia patients with antipsychotics-induced hyperprolactinemia were randomly assigned to aripiprazole group（n = 90） and control group（n = 90）, which were observed more than 26 weeks. Aripiprazole group patients were additionally treated with aripiprazole（5 mg·d-1）. Clinical global impression scale（CGIS） and the extrapyramidal symptoms rating scale（ESES） were administered, also prolactin（PRL）, treatment discontinuation ratio and time to discontinuation（TTD） were recorded at the baseline time and the end of 2,4,12,26 weeks. RESULTS PRL of aripiprazole group showed significant decline at the end of 4 weeks,and arrived a stable state at the end of 8 weeks. PRL of control group there was no change. At the end of 26 weeks, the treatment discontinuation ratio of aripiprazole group was 11.1%,of control group was 31.1%. At the end of 52 weeks, the treatment discontinuation ratio of aripiprazole group was 57. 8%,of control group was 76. 7%. There was significant difference of TTD between aripiprazole group and control group [ （297. 3 ± 92. 6） d vs （193. 5 ± 103.1 ）d, t = 6. 86, P = 0. 001 ]. CONCLUSION Combined a low dose aripiprazole to long term treatment for schizophrenia patient antipsychotics-induced hyperprolactinemia is effective and safe.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
2011年第10期843-846,共4页
Chinese Journal of Hospital Pharmacy
关键词
阿立哌唑
抗精神病药
高催乳素血症
有效性
对照
aripiprazole
antipsychotic
hyperprolactinemia
effectiveness
control study
